A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
Trial details
- Registry ID
- NCT04669028
- Drugs studied
- NE3107
TrialRedline tracks 4 clinical trials sponsored by BioVie Inc.: 1 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Study of NE3107 in Probable Alzheimer's DiseaseNCT04669028 | NE3107 | Completed | 2023-09-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| NE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191 | NE3107 | Completed | 2026-08-06Actual |
| A Study of NE3107 in Early Parkinson'sNCT06757010 | NE3107 | Completed | 2026-05-01Actual |
| A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory AscitesNCT04112199 | BIV201 continuous infusion | Terminated | 2023-05-08Actual |
Names as written in the registry records.
NCT06847191 · BioVie Inc.
Before: Active not recruiting. After: Completed.
NCT06847191 · BioVie Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in performance on the Cogstate Cognition battery*. After: Measure: Change from Baseline in performance on the Cogstate Cognition battery* Measure: Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a) Measure: Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a) Measure: Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a) Measure: Change from Baseline in SF-12 Health Survey (Physical Component Scores) Measure: Change from Baseline in SF-12 Health Survey (Mental Component Scores) Measure: Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional Malaise Measure: Composite Benefit Score.
Before: Estimated. After: Actual.
Before: Aug 2026. After: 6 Aug 2026.
NCT06757010 · BioVie Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in the MDS-UPDRS Part III. After: Measure: Monocyte Lymphocyte Ratio (MLR).
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 57 participants (actual).
Before: Estimated. After: Actual.
Before: Active not recruiting. After: Completed.
NCT06847191 · BioVie Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in performance on the Cogstate Cognition battery. After: Measure: Change from Baseline in performance on the Cogstate Cognition battery*.
Before: Estimated. After: Actual.
Before: 208 participants (planned). After: 203 participants (actual).
Before: Jun 2026. After: Aug 2026.
Before: Recruiting. After: Active not recruiting.
NCT06757010 · BioVie Inc.
Before: 1 Dec 2025. After: 1 May 2026.
Before: Recruiting. After: Active not recruiting.
NCT06847191 · BioVie Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in performance on the Cogstate Cognition battery. After: Measure: Change from Baseline in performance on the Cogstate Cognition battery.
NCT06847191 · BioVie Inc.
Before: Nov 2025. After: Jun 2026.